SPARX3 Study Logo

We are pleased to announce 25 sites are open for enrollment for SPARX3.

Aerobic exercise is a vital treatment for people living with Parkinson’s disease. Although anti-parkinsonian medication helps alleviate Parkinson’s symptoms, it is not known to slow the rate of disease progression. Aerobic exercise is a treatment with the most compelling evidence for its potential to slow Parkinson's disease progression. While both moderate- and high-intensity aerobic exercise provides health benefits, it is currently unclear which intensity is more effective for people with Parkinson’s. 

The SPARX3 (NCT04284436) study is the first randomized control trial designed to investigate the effects of moderate- and high-intensity aerobic exercise on disease progression in untreated patients with Parkinson’s.

Are you interested in becoming part of the SPARX3 research study

We are actively recruiting participants. Learn more about how you can become a participant here.